Węsierska‐Gądek et al., 2011 - Google Patents

Whether to target single or multiple CDKs for therapy? That is the question

Węsierska‐Gądek et al., 2011

Document ID
577123399861629098
Author
Węsierska‐Gądek J
Maurer M
Zulehner N
Komina O
Publication year
Publication venue
Journal of cellular physiology

External Links

Snippet

Complexes consisting of cyclin‐dependent kinases (CDKs) and their regulatory subunits (the cyclins) control the progression of normal mammalian cells through the cell cycle. However, during malignant transformation this regulatory apparatus malfunctions, allowing …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Similar Documents

Publication Publication Date Title
Węsierska‐Gądek et al. Whether to target single or multiple CDKs for therapy? That is the question
Łukasik et al. Cyclin-dependent kinases (CDK) and their role in diseases development–review
Gallorini et al. Cyclin-dependent kinase modulators and cancer therapy
Malumbres Physiological relevance of cell cycle kinases
Harper et al. The mammalian cell cycle: an overview
García-Reyes et al. The emerging role of cyclin-dependent kinases (CDKs) in pancreatic ductal adenocarcinoma
Pluta et al. Cyclin‐dependent kinases: Masters of the eukaryotic universe
Frade et al. Neuronal cell cycle: the neuron itself and its circumstances
Filhol et al. Protein kinase CK2 in health and disease: Cellular functions of protein kinase CK2: a dynamic affair
Giono et al. The p53 tumor suppressor participates in multiple cell cycle checkpoints
Lapenna et al. Cell cycle kinases as therapeutic targets for cancer
Malumbres et al. Mammalian cyclin-dependent kinases
Gopinathan et al. Established and novel Cdk/cyclin complexes regulating the cell cycle and development
Strebhardt Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Bergnes et al. Mitotic kinesins: prospects for antimitotic drug discovery
Maréchal et al. RPA-coated single-stranded DNA as a platform for post-translational modifications in the DNA damage response
McDonald et al. Cell cycle control as a basis for cancer drug development
Lei The MCM complex: its role in DNA replication and implications for cancer therapy
Chang et al. Deregulated Cdk5 triggers aberrant activation of cell cycle kinases and phosphatases inducing neuronal death
Zhang et al. Binding cavities and druggability of intrinsically disordered proteins
Dai et al. Cell cycle regulation and hematologic malignancies
Borgo et al. How can a traffic light properly work if it is always green? The paradox of CK2 signaling
Skladanowski et al. DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment
Mak et al. Pharmacological targeting the ATR–CHK1–WEE1 axis involves balancing cell growth stimulation and apoptosis
Liu et al. The substrates of Plk1, beyond the functions in mitosis